---
title: "Cluster Headache"
description: "Clinical decision support for cluster headache diagnosis and management including acute attack treatment and preventive therapy"
version: "1.0"
setting: "ED, HOSP, OPD"
status: draft
tags:
  - headache
  - cluster-headache
  - trigeminal-autonomic-cephalalgias
  - outpatient
---

<div class="draft-warning-banner">
  <div class="icon">⚠️</div>
  <div class="content">
    <div class="title">DRAFT - Pending Review</div>
    <div class="description">This plan requires physician review before clinical use.</div>
  </div>
</div>

# Cluster Headache

**DIAGNOSIS:** Cluster Headache
**ICD-10:** G44.009 (Cluster headache syndrome, unspecified)
**SCOPE:** Acute cluster headache attack treatment, transitional therapy, and preventive therapy for episodic and chronic cluster headache. Excludes other trigeminal autonomic cephalalgias (paroxysmal hemicrania, SUNCT/SUNA - separate protocols).

**STATUS:** Draft - Pending Review

---

**PRIORITY KEY:** STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting

---

## SECTION A: ACTION ITEMS

---

## 1. LABORATORY WORKUP

### 1A. Essential/Core Labs

| Test | Rationale | Target Finding | ED | HOSP | OPD | ICU |
|------|-----------|----------------|:--:|:----:|:---:|:---:|
| CBC | Baseline before starting preventive therapy; rule out infection | Normal | STAT | ROUTINE | ROUTINE | - |
| BMP | Baseline renal function before lithium or other preventives | Normal | STAT | ROUTINE | ROUTINE | - |
| TSH | Thyroid dysfunction can mimic or exacerbate headache; baseline for lithium | Normal (0.4-4.0 mIU/L) | - | ROUTINE | ROUTINE | - |
| LFTs | Baseline hepatic function before verapamil, valproate | Normal | - | ROUTINE | ROUTINE | - |

### 1B. Extended Workup (Second-line)

| Test | Rationale | Target Finding | ED | HOSP | OPD | ICU |
|------|-----------|----------------|:--:|:----:|:---:|:---:|
| Pituitary function panel (FSH, LH, prolactin, IGF-1, cortisol) | Atypical features or pituitary lesion on imaging | Normal | - | ROUTINE | ROUTINE | - |
| Lithium level | Monitoring when on lithium therapy | 0.6-1.0 mEq/L therapeutic range | - | ROUTINE | ROUTINE | - |
| Calcium, PTH | Lithium-induced hypercalcemia monitoring | Normal calcium; PTH not elevated | - | ROUTINE | ROUTINE | - |
| Free T4 | Lithium-induced thyroid dysfunction monitoring | Normal | - | ROUTINE | ROUTINE | - |
| BUN, creatinine | Lithium nephrotoxicity monitoring | Normal | - | ROUTINE | ROUTINE | - |

### 1C. Rare/Specialized (Refractory or Atypical)

| Test | Rationale | Target Finding | ED | HOSP | OPD | ICU |
|------|-----------|----------------|:--:|:----:|:---:|:---:|
| ESR, CRP | Atypical features; rule out giant cell arteritis in older patients | Normal | URGENT | ROUTINE | ROUTINE | - |
| Growth hormone stimulation test | Suspected pituitary adenoma with GH deficiency | Normal response | - | - | EXT | - |
| Sleep study (polysomnography) | Suspected obstructive sleep apnea as trigger | AHI <5 (normal) | - | - | ROUTINE | - |

---

## 2. DIAGNOSTIC IMAGING & STUDIES

### 2A. Essential/First-line

| Study | Timing | Target Finding | Contraindications | ED | HOSP | OPD | ICU |
|-------|--------|----------------|-------------------|:--:|:----:|:---:|:---:|
| MRI Brain with pituitary protocol | New diagnosis of cluster headache | Normal; exclude pituitary lesion, hypothalamic lesion, cavernous sinus pathology | MRI-incompatible devices, severe claustrophobia | URGENT | ROUTINE | ROUTINE | - |
| MRA Head | Suspected vascular etiology; atypical features | No aneurysm, dissection, vascular malformation | MRI contraindications | URGENT | ROUTINE | ROUTINE | - |

### 2B. Extended

| Study | Timing | Target Finding | Contraindications | ED | HOSP | OPD | ICU |
|-------|--------|----------------|-------------------|:--:|:----:|:---:|:---:|
| MRI orbits with contrast | Orbital pain, suspected retro-orbital pathology | No orbital mass, Tolosa-Hunt syndrome | Gadolinium allergy, severe renal impairment | URGENT | ROUTINE | EXT | - |
| CT Head non-contrast | MRI unavailable; acute presentation | No acute pathology | Pregnancy (relative) | STAT | STAT | - | - |
| CTA Head/Neck | Urgent vascular imaging if MRI unavailable | No aneurysm, dissection | Contrast allergy, CKD | STAT | URGENT | - | - |

### 2C. Rare/Specialized

| Study | Timing | Target Finding | Contraindications | ED | HOSP | OPD | ICU |
|-------|--------|----------------|-------------------|:--:|:----:|:---:|:---:|
| MRV Brain | Suspected cerebral venous thrombosis | Patent venous sinuses | MRI contraindications | URGENT | ROUTINE | EXT | - |
| CT sinuses | Suspected sinus pathology contributing | No sinusitis, mucocele | Pregnancy (relative) | - | ROUTINE | EXT | - |
| Carotid Doppler ultrasound | Suspected carotid dissection | No dissection | None | URGENT | ROUTINE | EXT | - |

---

## 3. TREATMENT

### 3A. Acute/Emergent (Abortive Therapy for Active Attacks)

| Treatment | Route | Indication | Dosing | Contraindications | Monitoring | ED | HOSP | OPD | ICU |
|-----------|-------|------------|--------|-------------------|------------|:--:|:----:|:---:|:---:|
| High-flow oxygen | INH | First-line abortive; most effective acute treatment | 100% at 12-15 L/min x 15-20 min :: INH :: :: 100% O2 via non-rebreather mask at 12-15 L/min for 15-20 min; patient seated, leaning forward; may repeat | Severe COPD with CO2 retention (relative) | SpO2; symptom resolution typically within 15 min | STAT | STAT | ROUTINE | - |
| Sumatriptan | SC | First-line abortive; rapid onset | 6 mg SC :: SC :: :: 6 mg SC at onset; may repeat after 1 hr if needed; max 12 mg/24hr | Uncontrolled HTN; CAD; prior MI/stroke; hemiplegic migraine; MAOIs; within 24h of ergot | Triptan sensation; monitor BP if cardiac risk factors | STAT | STAT | ROUTINE | - |
| Sumatriptan | Intranasal | Alternative to SC when injection not preferred | 20 mg intranasal :: Intranasal :: :: 20 mg intranasal at onset; may repeat after 2 hr; max 40 mg/24hr | Same as SC sumatriptan | Nasal irritation; triptan sensation | URGENT | URGENT | ROUTINE | - |
| Zolmitriptan | Intranasal | Alternative triptan; effective nasal delivery | 5 mg intranasal :: Intranasal :: :: 5 mg intranasal at onset; may repeat after 2 hr; max 10 mg/24hr | Same as sumatriptan | Triptan sensation; nasal discomfort | URGENT | URGENT | ROUTINE | - |
| Zolmitriptan | PO | Oral option when SC/nasal unavailable | 5 mg PO; 10 mg PO :: PO :: :: 5-10 mg PO at onset; may repeat after 2 hr; max 10 mg/24hr | Same as sumatriptan | Triptan sensation | URGENT | URGENT | ROUTINE | - |
| Octreotide | SC | Second-line; triptan contraindications or failure | 100 mcg SC :: SC :: :: 100 mcg SC at onset; may repeat once after 1 hr | Gallbladder disease; diabetes (may alter glucose) | Blood glucose; GI symptoms | URGENT | URGENT | EXT | - |
| Lidocaine | Intranasal | Adjunctive therapy; sphenopalatine ganglion block | 1 mL of 4-10% solution :: Intranasal :: :: Instill 1 mL of 4-10% lidocaine into nostril ipsilateral to pain; head tilted back 45 degrees toward affected side; may repeat x1 | Local anesthetic allergy | Numbness; bitter taste | URGENT | URGENT | ROUTINE | - |

### 3B. Transitional Therapy (Bridge Until Preventive Takes Effect)

| Treatment | Route | Indication | Dosing | Contraindications | Monitoring | ED | HOSP | OPD | ICU |
|-----------|-------|------------|--------|-------------------|------------|:--:|:----:|:---:|:---:|
| Prednisone | PO | Rapid cluster suppression; bridge to verapamil | 60 mg daily x 5 days; 40 mg daily x 5 days; 20 mg daily x 5 days :: PO :: :: Start 60-80 mg daily x 5 days, taper by 10-20 mg q5d over 2-3 weeks; limit to 2-3 courses/year | Active infection; uncontrolled diabetes; GI bleeding; psychosis history | Glucose; BP; mood changes; sleep | - | ROUTINE | ROUTINE | - |
| Dexamethasone | IV/PO | Alternative steroid; hospitalized patients | 8 mg IV/PO daily x 3-5 days :: IV/PO :: :: 4-8 mg IV or PO daily x 3-5 days, then taper or switch to prednisone | Same as prednisone | Glucose; BP | URGENT | URGENT | - | - |
| Greater occipital nerve block | SC | Transitional therapy; rapid reduction in attack frequency | 2-3 mL 2% lidocaine + 40 mg triamcinolone :: SC :: :: Inject 2-3 mL of 2% lidocaine + 40 mg triamcinolone (or 6 mg betamethasone) at greater occipital nerve ipsilateral to pain; may do bilaterally | Local anesthetic allergy; infection at site; anticoagulation (relative) | Immediate relief; vasovagal reaction; alopecia at injection site | - | ROUTINE | ROUTINE | - |
| Dihydroergotamine (DHE) | IV | Status cluster; refractory attacks; inpatient protocol | 0.5 mg IV q8h x 5 days; 1 mg IV q8h x 5 days :: IV :: :: 0.5-1 mg IV q8h (after test dose 0.25-0.5 mg) for 3-5 days; pretreat with antiemetic; requires telemetry | Pregnancy; CAD; uncontrolled HTN; peripheral vascular disease; use within 24h of triptan; hepatic/renal impairment; sepsis | BP; ECG monitoring; nausea; leg cramps; paresthesias | - | URGENT | - | - |
| Dihydroergotamine (DHE) | SC/IM | Home transitional therapy; bridge after inpatient protocol | 1 mg SC/IM at onset :: SC/IM :: :: 1 mg SC or IM at onset of attack; max 3 mg/24hr; max 6 mg/week | Same as IV DHE | Same as IV DHE | - | ROUTINE | ROUTINE | - |

### 3C. Second-line/Refractory (Acute Treatments)

| Treatment | Route | Indication | Dosing | Contraindications | Monitoring | ED | HOSP | OPD | ICU |
|-----------|-------|------------|--------|-------------------|------------|:--:|:----:|:---:|:---:|
| Sphenopalatine ganglion block | Intranasal | Refractory acute attacks; alternative to nerve block | 0.3 mL 0.5% bupivacaine :: Intranasal :: :: Apply 0.3 mL of 0.5% bupivacaine via intranasal catheter (Tx360, SphenoCath) to sphenopalatine ganglion | Local anesthetic allergy; nasal pathology | Local numbness; epistaxis; vasovagal | - | EXT | ROUTINE | - |
| Ketamine | Intranasal | Refractory attacks; investigational | 50-75 mg intranasal :: Intranasal :: :: 50-75 mg intranasal via atomizer; may repeat x1 | Uncontrolled HTN; psychosis; increased ICP | Dissociation; BP; HR | - | EXT | - | - |
| Ergotamine tartrate | SL/PO | Alternative when DHE unavailable | 2 mg SL at onset :: SL :: :: 2 mg sublingual at onset; may repeat 1-2 mg q30min; max 6 mg/attack, 10 mg/week | Same as DHE | Nausea; peripheral vasoconstriction | - | EXT | EXT | - |

### 3D. Preventive Therapies

| Treatment | Route | Indication | Dosing | Pre-Treatment Requirements | Contraindications | Monitoring | ED | HOSP | OPD | ICU |
|-----------|-------|------------|--------|---------------------------|-------------------|------------|:--:|:----:|:---:|:---:|
| Verapamil | PO | First-line preventive; episodic and chronic CH | 80 mg TID; 120 mg TID; 160 mg TID; 240 mg TID :: PO :: :: Start 80 mg TID; increase by 80 mg q10-14d as tolerated; target 240-480 mg TID (720-960 mg/day total); some patients require up to 960 mg/day | Baseline ECG; repeat ECG with each dose increase | Second/third-degree heart block; sick sinus syndrome; severe hypotension; decompensated HF; concurrent beta-blocker (relative) | ECG before each dose increase (monitor PR interval >0.24s or 40% increase); HR; BP; constipation; edema | - | ROUTINE | ROUTINE | - |
| Lithium carbonate | PO | Chronic cluster headache; verapamil failure/intolerance | 300 mg BID; 300 mg TID; 450 mg BID; 600 mg BID :: PO :: :: Start 300 mg BID; titrate by 300 mg q3-7d to target level 0.6-1.0 mEq/L; typical dose 600-1200 mg/day | Baseline TSH, BMP, calcium, ECG | Renal impairment; sick sinus syndrome; pregnancy; Brugada syndrome; concurrent NSAIDs/ACE-I/thiazides | Lithium level q1wk during titration, then q1-3mo; TSH, creatinine, calcium q3-6mo; tremor; polyuria | - | ROUTINE | ROUTINE | - |
| Topiramate | PO | Preventive; especially with comorbid migraine | 25 mg qHS; 50 mg BID; 75 mg BID; 100 mg BID :: PO :: :: Start 25 mg qHS; increase by 25 mg/wk; target 100-200 mg/day divided BID | None | Glaucoma; kidney stones; pregnancy; metabolic acidosis | Cognitive effects; paresthesias; weight; serum bicarbonate; kidney stones | - | ROUTINE | ROUTINE | - |
| Galcanezumab (Emgality) | SC | FDA-approved for episodic cluster headache; CGRP mAb | 300 mg SC monthly :: SC :: :: 300 mg SC (3 consecutive 100 mg injections) at onset of cluster period; repeat monthly during cluster period | None | Hypersensitivity to galcanezumab | Injection site reactions; constipation | - | - | ROUTINE | - |
| Melatonin | PO | Adjunctive prevention; circadian dysregulation | 10 mg qHS; 15 mg qHS; 20 mg qHS :: PO :: :: 10-20 mg PO 30 min before bedtime; may help regulate cluster periodicity | None | None significant | Sedation; morning grogginess | - | ROUTINE | ROUTINE | - |
| Valproate/Divalproex | PO | Alternative preventive; especially with comorbid epilepsy/mood disorder | 250 mg BID; 500 mg BID; 500 mg ER daily; 1000 mg ER daily :: PO :: :: Start 250 mg BID or 500 mg ER daily; titrate to 500-1500 mg/day | LFTs, CBC | Hepatic disease; pregnancy (teratogen); urea cycle disorders; pancreatitis history | LFTs q6mo; CBC; ammonia if AMS; weight; hair loss; tremor | - | ROUTINE | ROUTINE | - |
| Baclofen | PO | Alternative preventive; trigeminal autonomic pathway modulation | 5 mg TID; 10 mg TID; 20 mg TID :: PO :: :: Start 5 mg TID; titrate by 5 mg/dose q3d; target 30-60 mg/day divided TID | None | Withdrawal if abrupt discontinuation; renal impairment (reduce dose) | Sedation; weakness; withdrawal syndrome; do not stop abruptly | - | ROUTINE | ROUTINE | - |
| Gabapentin | PO | Alternative preventive; neuropathic pain component | 300 mg qHS; 300 mg TID; 600 mg TID; 900 mg TID :: PO :: :: Start 300 mg qHS; titrate by 300 mg q1-3d; target 1800-3600 mg/day divided TID | None | Reduce dose in renal impairment | Sedation; dizziness; edema; weight gain | - | ROUTINE | ROUTINE | - |

### 3E. Refractory/Interventional Therapies

| Treatment | Route | Indication | Dosing | Pre-Treatment Requirements | Contraindications | Monitoring | ED | HOSP | OPD | ICU |
|-----------|-------|------------|--------|---------------------------|-------------------|------------|:--:|:----:|:---:|:---:|
| Occipital nerve stimulation | Implant | Chronic refractory cluster headache; failed multiple preventives | N/A - surgical implant :: Implant :: :: Percutaneous or surgical implantation of occipital nerve stimulator; specialist referral required | Neurosurgical evaluation; psychological screening; failed at least 3 preventive medications | Active infection; coagulopathy; psychiatric instability | Post-implant follow-up; battery life; lead migration | - | - | EXT | - |
| Deep brain stimulation | Implant | Severe refractory chronic CH; last resort | N/A - surgical implant :: Implant :: :: Targeting posterior hypothalamus; investigational; specialist center only | Extensive workup; ethics committee review; failed all other options | Same as ONS; structural brain abnormality | Long-term neurological monitoring | - | - | EXT | - |
| Sphenopalatine ganglion stimulation | Implant | Refractory CH; acute and preventive effects | N/A - surgical implant :: Implant :: :: Pulsante SPG microstimulator; patient-controlled acute therapy | Neurosurgical evaluation; imaging confirmation | Facial/jaw abnormalities; active infection | Lead integrity; battery; efficacy | - | - | EXT | - |
| Radiofrequency ablation trigeminal ganglion | Procedure | Refractory chronic CH; trigeminal nerve modulation | N/A - procedure :: Procedure :: :: Percutaneous RF ablation; provides 6-18 months relief; may need repeat | Facial imaging; failed medical therapy | Anticoagulation; infection; facial numbness intolerance | Facial sensation; corneal reflex; recurrence | - | - | EXT | - |

---

## 4. OTHER RECOMMENDATIONS

### 4A. Referrals & Consults

| Recommendation | ED | HOSP | OPD | ICU |
|----------------|:--:|:----:|:---:|:---:|
| Headache specialist/Neurology referral for diagnosis confirmation and preventive therapy optimization | URGENT | ROUTINE | ROUTINE | - |
| Pain management referral for interventional procedures (nerve blocks, neuromodulation evaluation) in refractory cases | - | ROUTINE | ROUTINE | - |
| Sleep medicine evaluation for polysomnography if obstructive sleep apnea suspected as cluster trigger | - | - | ROUTINE | - |
| Endocrinology referral if pituitary abnormality identified on imaging or atypical hormone levels | - | ROUTINE | ROUTINE | - |
| Neurosurgery consultation for neuromodulation or ablative procedures in medically refractory cases | - | - | EXT | - |
| Cardiology clearance before initiating high-dose verapamil in patients with cardiac history | - | ROUTINE | ROUTINE | - |
| Psychiatry referral for suicidal ideation screening given high depression/suicide risk in cluster headache patients | URGENT | ROUTINE | ROUTINE | - |

### 4B. Patient Instructions

| Recommendation | ED | HOSP | OPD |
|----------------|:--:|:----:|:---:|
| Return immediately for sudden severe headache different from typical cluster attacks which may indicate new pathology | STAT | - | ROUTINE |
| Keep high-flow oxygen available at home during cluster period for acute attack treatment | - | ROUTINE | ROUTINE |
| Use sumatriptan injection at first sign of attack for fastest relief; do not wait for pain to worsen | URGENT | ROUTINE | ROUTINE |
| Maintain detailed headache diary including attack timing, duration, severity, and treatment response | - | ROUTINE | ROUTINE |
| Avoid known triggers during cluster period especially alcohol (even small amounts), strong odors, and napping | - | ROUTINE | ROUTINE |
| Do not abruptly stop preventive medications especially lithium and baclofen which require gradual taper | - | ROUTINE | ROUTINE |
| Carry injectable sumatriptan at all times during active cluster period for emergency use | - | ROUTINE | ROUTINE |
| Alert healthcare providers to cluster headache diagnosis as this affects anesthesia and medication choices | - | ROUTINE | ROUTINE |

### 4C. Lifestyle & Prevention

| Recommendation | ED | HOSP | OPD |
|----------------|:--:|:----:|:---:|
| Strict alcohol avoidance during entire cluster period as even small amounts trigger attacks | - | ROUTINE | ROUTINE |
| Maintain regular sleep schedule with consistent bedtime and wake time to regulate circadian rhythm | - | ROUTINE | ROUTINE |
| Avoid daytime napping during cluster period as sleep transitions can trigger attacks | - | ROUTINE | ROUTINE |
| Smoking cessation to reduce vascular risk and potential cluster exacerbation | - | ROUTINE | ROUTINE |
| Avoid high altitude exposure during cluster period if altitude is a known trigger | - | ROUTINE | ROUTINE |
| Avoid vasodilators (nitroglycerin, sildenafil) during cluster period as these trigger attacks | - | ROUTINE | ROUTINE |
| Screen for and treat obstructive sleep apnea as treatment may reduce cluster frequency | - | ROUTINE | ROUTINE |
| Stress management techniques as emotional stress may influence cluster cycle onset | - | ROUTINE | ROUTINE |
| Avoid strong chemical odors (solvents, perfumes, gasoline) which can trigger attacks in some patients | - | ROUTINE | ROUTINE |

---

## SECTION B: REFERENCE

---

## 5. DIFFERENTIAL DIAGNOSIS

| Alternative Diagnosis | Key Distinguishing Features | Tests to Differentiate |
|-----------------------|----------------------------|------------------------|
| Migraine | Longer duration (4-72 hrs); bilateral or alternating sides; nausea/vomiting prominent; photophobia/phonophobia; no autonomic features | Clinical criteria (ICHD-3); MRI if new onset |
| Paroxysmal hemicrania | Shorter attacks (2-30 min); more frequent (>5/day); absolute response to indomethacin | Indomethacin trial (150-225 mg/day); complete response diagnostic |
| SUNCT/SUNA | Very brief attacks (seconds to minutes); very frequent (up to 200/day); triggered by cutaneous stimuli | Clinical criteria; may have refractory period; no response to indomethacin |
| Trigeminal neuralgia | Electric shock-like pain; seconds duration; triggered by touch, chewing, talking; refractory period | MRI for vascular compression; response to carbamazepine |
| Hemicrania continua | Continuous baseline pain with superimposed exacerbations; unilateral; autonomic features | Absolute response to indomethacin diagnostic |
| Primary stabbing headache | Ultra-short jabs (seconds); unpredictable location; no autonomic features | Clinical diagnosis; exclusion of secondary causes |
| Secondary cluster headache | Atypical features; pituitary or hypothalamic lesion; carotid dissection | MRI with pituitary protocol; MRA head/neck |
| Tolosa-Hunt syndrome | Painful ophthalmoplegia; orbital pain; CN III, IV, VI involvement | MRI orbits with contrast; CSF if needed; steroid response |
| Giant cell arteritis | Age >50; scalp tenderness; jaw claudication; visual symptoms; elevated ESR/CRP | ESR, CRP; temporal artery biopsy |
| Carotid dissection | Neck pain; Horner syndrome; stroke symptoms | CTA or MRA neck; carotid ultrasound |

---

## 6. MONITORING PARAMETERS

| Parameter | Frequency | Target/Threshold | Action if Abnormal | ED | HOSP | OPD | ICU |
|-----------|-----------|------------------|-------------------|:--:|:----:|:---:|:---:|
| Attack frequency diary | Daily during cluster | 50% reduction with preventive | Escalate preventive therapy; consider transitional bridge | - | ROUTINE | ROUTINE | - |
| ECG (if on verapamil) | Baseline and with each dose increase | PR interval <0.28s and <40% increase from baseline | Hold dose increase; may need cardiology clearance | - | ROUTINE | ROUTINE | - |
| Heart rate (if on verapamil) | Each visit | HR >50 bpm | Reduce dose; consider alternative | - | ROUTINE | ROUTINE | - |
| Lithium level | Weekly during titration, then q1-3 months | 0.6-1.0 mEq/L | Adjust dose; assess renal function if unexpected level | - | ROUTINE | ROUTINE | - |
| TSH (if on lithium) | Baseline, 3 months, then q6 months | Normal (0.4-4.0 mIU/L) | Endocrine referral; may need thyroid replacement | - | ROUTINE | ROUTINE | - |
| BUN/Creatinine (if on lithium) | Baseline, q1-3 months | Normal; no progressive rise | Dose reduction; nephrology referral if progressive | - | ROUTINE | ROUTINE | - |
| Calcium (if on lithium) | Baseline, q6 months | Normal | Evaluate for hyperparathyroidism | - | ROUTINE | ROUTINE | - |
| Serum bicarbonate (if on topiramate) | Baseline, 3 months | >18 mEq/L | Reduce dose or discontinue | - | ROUTINE | ROUTINE | - |
| Depression/Suicidal ideation screening | Each visit | PHQ-9 <10; no suicidal ideation | Urgent psychiatric referral; crisis intervention | URGENT | ROUTINE | ROUTINE | - |
| Oxygen saturation (during O2 therapy) | During treatment | >94% | Adjust flow rate | STAT | STAT | ROUTINE | - |

---

## 7. DISPOSITION CRITERIA

| Disposition | Criteria |
|-------------|----------|
| Discharge home | Acute attack aborted with oxygen/triptan; stable; access to home oxygen and rescue medications; follow-up arranged |
| Admit to floor | Status cluster (continuous attacks); requires IV DHE protocol; suicidal ideation requiring monitoring; oral intake compromised |
| Admit to ICU | Rare; only if hemodynamic instability, cardiac arrhythmia from verapamil, or severe psychiatric crisis |
| Outpatient follow-up | Within 1-2 weeks if in active cluster period; 2-4 weeks after initiating new preventive; q3 months during remission |
| Transfer to headache center | Refractory to multiple preventives; candidate for neuromodulation; requires specialized interventional procedures |

---

## 8. EVIDENCE & REFERENCES

| Recommendation | Evidence Level | Source |
|----------------|----------------|--------|
| High-flow oxygen (100% at 12-15 L/min) first-line abortive | Class I, Level A | [Cohen et al. JAMA 2009](https://pubmed.ncbi.nlm.nih.gov/20040554/) |
| Subcutaneous sumatriptan 6 mg effective for acute attacks | Class I, Level A | [The Sumatriptan Cluster Headache Study Group. NEJM 1991](https://pubmed.ncbi.nlm.nih.gov/1652413/) |
| Intranasal zolmitriptan 5-10 mg effective for acute attacks | Class I, Level A | [Cittadini et al. Neurology 2006](https://pubmed.ncbi.nlm.nih.gov/17101886/) |
| Verapamil first-line preventive for episodic and chronic CH | Class I, Level C (expert consensus) | [May et al. Cephalalgia 2006](https://pubmed.ncbi.nlm.nih.gov/16919064/) |
| Galcanezumab FDA-approved for episodic cluster headache | Class I, Level A | [Goadsby et al. NEJM 2019](https://pubmed.ncbi.nlm.nih.gov/31291515/) |
| Greater occipital nerve block effective as transitional therapy | Class II, Level B | [Ambrosini et al. Pain 2005](https://pubmed.ncbi.nlm.nih.gov/15885916/) |
| Lithium effective for chronic cluster headache prevention | Class II, Level B | [Steiner et al. Headache 1997](https://pubmed.ncbi.nlm.nih.gov/9227503/) |
| Prednisone taper effective transitional therapy | Class II, Level C | [Obermann et al. Curr Pain Headache Rep 2011](https://pubmed.ncbi.nlm.nih.gov/21069491/) |
| Octreotide effective when triptans contraindicated | Class II, Level B | [Matharu et al. Ann Neurol 2004](https://pubmed.ncbi.nlm.nih.gov/15349875/) |
| Melatonin 10 mg may reduce attack frequency | Class II, Level C | [Leone et al. Cephalalgia 1996](https://pubmed.ncbi.nlm.nih.gov/8980856/) |
| Occipital nerve stimulation for refractory chronic CH | Class III, Level C | [Burns et al. Lancet 2007](https://pubmed.ncbi.nlm.nih.gov/17336639/) |
| European Headache Federation cluster headache guidelines | Guideline | [Mitsikostas et al. J Headache Pain 2023](https://pubmed.ncbi.nlm.nih.gov/36577931/) |

---

## CHANGE LOG

**v1.0 (January 27, 2026)**
- Initial template creation
- Comprehensive acute abortive, transitional, and preventive therapy coverage
- Includes FDA-approved galcanezumab for episodic cluster headache
- Structured dosing format for order sentence generation
- Emphasis on high-flow oxygen as first-line treatment
- Verapamil with ECG monitoring protocol
- Differential diagnosis including other trigeminal autonomic cephalalgias
